CannBioRx Life Sciences Corp. Statistics
Share Statistics
CannBioRx Life Sciences Corp. has 350.64M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 350.64M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.08 and the forward PE ratio is null.
| PE Ratio | -0.08 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -12.05 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | n/a |
Enterprise Valuation
CannBioRx Life Sciences Corp. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of -8.25.
| Current Ratio | 0.72 |
| Quick Ratio | 0.72 |
| Debt / Equity | -8.25 |
| Total Debt / Capitalization | 113.79 |
| Cash Flow / Debt | -10.36 |
| Interest Coverage | -300649.15 |
Financial Efficiency
Return on equity (ROE) is 156.07% and return on capital (ROIC) is -1301.55%.
| Return on Equity (ROE) | 156.07% |
| Return on Assets (ROA) | -3.79% |
| Return on Capital (ROIC) | -1301.55% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.98M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -2.35M |
| Effective Tax Rate | 0.11 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.25, so CannBioRx Life Sciences Corp.'s price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 44.78 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, CannBioRx Life Sciences Corp. had revenue of $0 and earned -$19.94M in profits. Earnings per share was $-52.6.
| Revenue | 0 |
| Gross Profit | -105.67K |
| Operating Income | -13.48M |
| Net Income | -19.94M |
| EBITDA | -22.13M |
| EBIT | - |
| Earnings Per Share (EPS) | -52.6 |
Balance Sheet
The company has $1.98M in cash and $1.05M in debt, giving a net cash position of $921.74K.
| Cash & Cash Equivalents | 1.98M |
| Total Debt | 1.05M |
| Net Cash | 921.74K |
| Retained Earnings | -127.34M |
| Total Assets | 10.47M |
| Working Capital | -5.16M |
Cash Flow
In the last 12 months, operating cash flow was -$10.92M and capital expenditures $3, giving a free cash flow of -$10.92M.
| Operating Cash Flow | -10.92M |
| Capital Expenditures | 3 |
| Free Cash Flow | -10.92M |
| FCF Per Share | -28.82 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ATNFW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ATNFW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -18.41 |
| Piotroski F-Score | 3 |